• A. Rigamonti
Part of the Emergency Management in Neurology book series (EMN)


Botulism is a potentially fatal neuroparalytic syndrome caused by the action of a neurotoxin produced by the bacterium Clostridium botulinum. Clostridium botulinum is a diverse group of anaerobic gram-positive bacteria that produces spores. The spores are resistant to approximately 100°C for 5 h. These bacteria are ubiquitous and can be easily isolated from the surface of fruit, vegetables, and fish and are present in soil and in marine sediment around the world [1].


  1. 1.
    Dowell VR Jr (1984) Botulism and tetanus: selected epidemiologic and microbiologic aspects. Rev Infect Dis 6(suppl 1):S202CrossRefPubMedGoogle Scholar
  2. 2.
    Abrutyn E (1998) Botulism. In: Fauci AS, Isselbacher KJ, Braunwald E (eds) Principles of internal medicine, 14th edn. McGraw-Hill, New York, p 904Google Scholar
  3. 3.
    Jin R, Rummel A, Binz T, Brunger AT (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444:1092CrossRefPubMedGoogle Scholar
  4. 4.
    Chai Q, Arndt JW, Dong M et al (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444:1096CrossRefPubMedGoogle Scholar
  5. 5.
    Black JD, Dolly JO (1986) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 103:535CrossRefPubMedGoogle Scholar
  6. 6.
    Bleck TP (2005) Clostridium botulinum (botulism). In: Mandel GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 6th edn. Churchill Livingstone, Philadelphia, p 2822Google Scholar
  7. 7.
    Padua L, Aprile I, Monaco ML et al (1999) Neurophysiological assessment in the diagnosis of botulism: usefulness of single-fiber EMG. Muscle Nerve 22:1388CrossRefPubMedGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention (CDC) (2010) Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 59:299Google Scholar
  9. 9.
    FDA news release. FDA approves first botulism antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. Accessed 25 March 2013
  10. 10.
    Sellin LC (1984) Botulism- an update. Mil Med 149:12PubMedGoogle Scholar
  11. 11.
    American Academy of Pediatrics (2015) Botulism and infant botulism (Clostridium botulinum). In: Kimberlin DW, Brady MT, Jackson MA, Long SS (eds) Red Book: 2015 Report of the Committee on Infectious Diseases, 30th edn. American Academy of Pediatrics, Elk Grove Village, p 294Google Scholar
  12. 12.
    Varma JK, Katsitadze G, Moiscrafishvili M et al (2004) Signs and symptoms predictive of death in patients with foodborne botulism--Republic of Georgia, 1980-2002. Clin Infect Dis 39(3):357CrossRefPubMedGoogle Scholar
  13. 13.
    Arnon SS, Schechter R, Maslanka SE et al (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462CrossRefPubMedGoogle Scholar
  14. 14.
    Norwood F, Dhanjal M, Hill M et al (2014) Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 85(5):538–543CrossRefPubMedGoogle Scholar
  15. 15.
    Sussman J, Farrugia ME, Maddison P et al (2015) Myasthenia gravis: association of British Neurologists’ management guidelines. Pract Neurol 15(3):199–206CrossRefPubMedGoogle Scholar
  16. 16.
    Kerty E, Elsais A, Argov Z et al (2014) EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21(5):687–693CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of NeuroscienceASST LeccoLeccoItaly

Personalised recommendations